Home
NTLA
NTLA News

Latest Intellia Therapeutics Inc. (NTLA) News on October 30, 2025

Intellia (NTLA) Soars 13% to Fresh High

Insider Monkey

9 days ago

Intellia (NTLA) Soars 13% to Fresh High

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought

Motley Fool

a month ago

Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire

a month ago

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

Zacks

a month ago

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Premarket Thursday

MT Newswires

a month ago

Intellia Therapeutics Completes Enrollment in Phase 3 Study of Potential Hereditary Angioedema Treatment

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

GlobeNewswire

a month ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

3 Promising Genomics Stocks to Keep an Eye On in 2025

Zacks

4 months ago

3 Promising Genomics Stocks to Keep an Eye On in 2025

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Zacks

4 months ago

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress

Insider Monkey

4 months ago

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

Simply Wall St.

4 months ago

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Zacks

4 months ago

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Investor's Business Daily

4 months ago

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

Insider Monkey

4 months ago

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

BioPharma Dive

4 months ago

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

MT Newswires

4 months ago

Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

GlobeNewswire

4 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks

5 months ago

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Zacks

5 months ago

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks

5 months ago

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Will Tesla have to play catch up to Waymo's robotaxis?

Yahoo Finance Video

5 months ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

Yahoo Finance

5 months ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

Statement by Minister Guilbeault on Portuguese Heritage Month

CNW Group

5 months ago

Statement by Minister Guilbeault on Portuguese Heritage Month

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

PR Newswire

5 months ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

GlobeNewswire

5 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

5 months ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

Man Utd sign Brazil forward Cunha from Wolves

AFP

5 months ago

Man Utd sign Brazil forward Cunha from Wolves

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

Moneywise

5 months ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Zacks

5 months ago

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Intellia stock dips following safety event in Phase III gene therapy trial

Clinical Trials Arena

5 months ago

Intellia stock dips following safety event in Phase III gene therapy trial

Morningstar Research

5 months ago

Analyst Report: Intellia Therapeutics, Inc.

MT Newswires

5 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday

MT Newswires

5 months ago

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

Investing.com

5 months ago

Intellia stock tumbles on safety concerns

MT Newswires

5 months ago

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating

Intellia filing spurs safety concerns over CRISPR drug

BioPharma Dive

5 months ago

Intellia filing spurs safety concerns over CRISPR drug

MT Newswires

5 months ago

Sector Update: Health Care Stocks Steady-to-Lower Pre-Bell Monday

MT Newswires

5 months ago

Top Premarket Gainers

MT Newswires

5 months ago

Intellia Therapeutics Says Drug Shows Potential in Phase 1 Transthyretin Amyloidosis Trial

GlobeNewswire

5 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

Zacks

6 months ago

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

Simply Wall St.

6 months ago

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Simply Wall St.

6 months ago

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

Zacks

6 months ago

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

MT Newswires

6 months ago

Truist Securities Cuts Price Target on Intellia Therapeutics to $33 From $50, Maintains Buy Rating

MT Newswires

6 months ago

RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

GuruFocus.com

6 months ago

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Morningstar Research

6 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Zacks

6 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

GlobeNewswire

6 months ago

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Zacks

6 months ago

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

6 months ago

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks

6 months ago

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Zacks

6 months ago

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

GlobeNewswire

6 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

6 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Zacks

6 months ago

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Trump’s FDA Sends a Bullish Signal to Biotech

The Wall Street Journal

6 months ago

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Investor's Business Daily

6 months ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

MT Newswires

6 months ago

Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research

MT Newswires

6 months ago

Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Insider Monkey

7 months ago

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Clinical Trials Arena

7 months ago

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Pharmaceutical Technology

7 months ago

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire

7 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

MT Newswires

7 months ago

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Insider Monkey

7 months ago

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

7 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks

7 months ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

Zacks

7 months ago

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

MT Newswires

7 months ago

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

GlobeNewswire

7 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

7 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

The Fly

8 months ago

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

MT Newswires

8 months ago

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 months ago

Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

8 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Zacks

8 months ago

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

MT Newswires

8 months ago

RBC Cuts Price Target on Intellia Therapeutics to $37 From $47, Keeps Outperform, Speculative Risk

MT Newswires

8 months ago

JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13

Morningstar Research

8 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com

8 months ago

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Intellia Therapeutics Inc Earnings Call

MT Newswires

8 months ago

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Zacks

8 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire

8 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

8 months ago

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

What's in Store for These 5 Biotech Stocks This Earnings Season?

Zacks

8 months ago

What's in Store for These 5 Biotech Stocks This Earnings Season?

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Motley Fool

8 months ago

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

8 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Zacks

8 months ago

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

GlobeNewswire

8 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Insider Monkey

8 months ago

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Zacks

8 months ago

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Share on Social Networks: